Other
Hemoglobin
0
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Hemoglobin is an early-stage landscape with 0 programs across 2 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
13
clinical trials
Completed10 · 77%
Terminated2 · 15%
Recruiting1 · 8%
Clinical Trials
Trial Activity
13 trials
Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients
Completed·—·N/A·NCT07115121·40 enrolled
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00440466·430 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00440466·430 enrolledImpact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin
Completed·—·Phase 4·NCT02641210·63 enrolled
Acquired Methemoglobinemia Observational Registry
Completed·—·N/A·NCT03542760·24 enrolled
Effect of Vitamin E Supplementation on Hemoglobin Levels in Healthy Adults
Completed·—·Phase 1/2·NCT02181348·357 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)